Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including ...

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to …

RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a ...
TipRanks on MSN

Eisai, Biogen announce U.S. availability of LEQEMBI IQLIK

Eisai Co. (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, U.S. brand name: LEQEMBI IQLIKTM, ...

Ozempic vs Metformin for weight loss: Which is right for me?

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
TipRanks on MSN

Eisai, Biogen announces Leqembi Iqlik availability in the U.S.

Eisai (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, or Leqembi Iqlik, is now available in the U.S. as a ...

Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback

Novo Nordisk A/S faces competition in obesity drug development space; pipeline innovations & long-term outlook. Read why NVO ...

Costco selling weight loss injections at a discount—but are they the smartest spend?

As semaglutide hits pharmacy shelves for $499, doctors weigh the pros and cons of brand-name vs. compounded meds.
Targeted Oncology

Administration of Amivantamab/Lazertinib

An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the ...